

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

12 Jun 2026

### Efficacy of pre-emptive metoclopramide on patients' pain, discomfort and nausea associated with NG Tube insertion

#### Protocol summary

##### Study aim

1- Determine the effect of metoclopramide injection before NG-Tube on the severity of pain caused by NG-Tube. 2- Determine the effect of metoclopramide injections before NG-Tube injection on patient discomfort. 3. Determine the effect of metoclopramide injection before NG-Tube on the incidence of NG-Tube nausea and vomiting.

##### Design

A randomized, controlled, double-blind, placebo-controlled clinical trial

##### Settings and conduct

The study is performed in the hospital emergency department and in patients who require NG tube. Patients were randomly divided into case (metoclopramide) and control (placebo) groups. The project associate will label the syringes without the knowledge of the researcher, physician, nurse, and patient evaluator, and all NG tube insertions will be performed by a person who is unaware of the placement of the patients into two groups. The degree of discomfort as well as the severity of pain and nausea will be assessed immediately and 30 and 60 minutes after the procedure using the VAS criteria in the two groups.

##### Participants/Inclusion and exclusion criteria

Patients with an indication of NG tube and over 18 years old who are willing to participate in the study are included. patients with unconsciousness, pregnancy, unstable hemodynamic status, nasal bleeding at study time, nasal anatomical problems, sensitivity to metoclopramide, use of metoclopramide interfering drugs, patients presenting with nausea and vomiting, trauma patients and patients have more than twice attempted a NGT insertion. Yard is not included in the study.

##### Intervention groups

For the case group, 10 mg metoclopramide will be administered intravenously 15 minutes before the procedure, and for the control group, the same volume of

normal saline will be administered.

##### Main outcome variables

Discomfort; severity of pain; nausea

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180717040509N4**

Registration date: **2020-04-02, 1399/01/14**

Registration timing: **retrospective**

Last update: **2020-04-02, 1399/01/14**

Update count: **0**

##### Registration date

2020-04-02, 1399/01/14

##### Registrant information

##### Name

Mahboubeh Eslami

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 11 3321 7982

##### Email address

m.eslami@mazums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2015-09-01, 1394/06/10

##### Expected recruitment end date

2016-02-20, 1394/12/01

##### Actual recruitment start date

2015-09-01, 1394/06/10

##### Actual recruitment end date

2016-02-20, 1394/12/01

#### **Trial completion date**

2016-02-20, 1394/12/01

#### **Scientific title**

Efficacy of pre-emptive metoclopramide on patients' pain, discomfort and nausea associated with NG Tube insertion

#### **Public title**

effect of metoclopramide in pain and nausea

#### **Purpose**

Treatment

#### **Inclusion/Exclusion criteria**

##### **Inclusion criteria:**

Patients with NG tube Indication

##### **Exclusion criteria:**

less than 18 years old Lack of consciousness Patients with unstable hemodynamic status (systolic blood pressure less than 90 mmHg) Having a nose bleed Anatomical problems in the nose Traumatic patients Sensitivity to metoclopramide Use of metoclopramide interfering drugs (anticholinergic, digoxin, levodopa, tetracycline) Pregnancy Patients with nausea and vomiting problem NG tube more than twice

#### **Age**

From **18 years** old

#### **Gender**

Both

#### **Phase**

3

#### **Groups that have been masked**

- Participant
- Care provider
- Outcome assessor
- Data analyser

#### **Sample size**

Target sample size: **46**

Actual sample size reached: **46**

#### **Randomization (investigator's opinion)**

Randomized

#### **Randomization description**

Simple randomization with Independent samples The 46 sample units were divided into two independent groups with equal volume according to the random number table. Random Unit: Individual Random Tool: Random Number Table

#### **Blinding (investigator's opinion)**

Double blinded

#### **Blinding description**

Participants, physicians, nurses, and patient evaluators are not aware of the group allocation

#### **Placebo**

Used

#### **Assignment**

Parallel

#### **Other design features**

### **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

##### **Name of ethics committee**

Ethics Committee of Mazandaran University of Medical Sciences

##### **Street address**

Moallem Ave, Moallem Square, Deputy of Research and Technology of Mazandaran University of Medical Sciences

##### **City**

Sari

##### **Province**

Mazandaran

##### **Postal code**

4817844818

##### **Approval date**

2015-08-31, 1394/06/09

##### **Ethics committee reference number**

IR.MAZUMS.REC.94-1477

## **Health conditions studied**

### 1

#### **Description of health condition studied**

Pain, nausea and discomfort from nasal-gastric tube insertion

##### **ICD-10 code**

##### **ICD-10 code description**

## **Primary outcomes**

### 1

#### **Description**

Pain, nausea and discomfort

#### **Timepoint**

30 and 60 minutes after NG tube insertion

#### **Method of measurement**

Visual Analgesic Score

## **Secondary outcomes**

### 1

#### **Description**

Bleeding and vomiting after NG tube insertion

#### **Timepoint**

30 and 60 minutes after NG tube placement

#### **Method of measurement**

Visual Analgesic Score

## **Intervention groups**

### 1

#### **Description**

Intervention group: For the intervention group 15

minutes before NG tube placement, 10 mg metoclopramide (manufactured by Alawi Pharmaceutical Company) will be injected intravenously.

**Category**

Treatment - Drugs

**2****Description**

Control group: Patients in the control group will receive 10 mg of normal saline (as placebo) 15 minutes before NG tube placement.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Emam Khomeini Hospital

**Full name of responsible person**

seyed Mohammad Hoseininejad

**Street address**

Razi Street

**City**

Sari

**Province**

Mazandaran

**Postal code**

۳۳۱۳۱ -۴۸۱۶۶

**Phone**

+98 11 3336 1700

**Fax**

+98 11 3336 3754

**Email**

drhoseininejad@yahoo.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Majid Saeidi

**Street address**

Moalem Sqr

**City**

Sari

**Province**

Mazandaran

**Postal code**

1133257230

**Phone**

+98 11 3325 7230

**Fax**

+98 11 3326 1244

**Email**

majsaeedi@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Sari University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad Hoseininejad

**Position**

Associate Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Emergency Medicine

**Street address**

Amir Mazandarani Street

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816633131

**Phone**

+98 11 3336 1700

**Fax**

+98 11 3337 0881

**Email**

drhoseininejad@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad Hoseininejad

**Position**

Associate Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Emergency Medicine

**Street address**

Amir Mazandarani Street  
**City**  
Sari  
**Province**  
Mazandaran  
**Postal code**  
4816633131  
**Phone**  
+98 11 3336 1700  
**Fax**  
+98 11 3337 0881  
**Email**  
drhoseininejad@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Mazandaran University of Medical Sciences  
**Full name of responsible person**  
Mahboubeh Eslami  
**Position**  
Consultant  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Medical Informatics  
**Street address**  
Emam Khomeini Hospital, Amir Mazandarani Street  
**City**  
Sari  
**Province**

Mazandaran  
**Postal code**  
4816633131  
**Phone**  
+98 11 3321 7982  
**Fax**  
**Email**  
m.eslami@mazums.ac.ir

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

### Justification/reason for indecision/not sharing IPD

No more information

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Not applicable